

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Nobivac Respira Bb suspension for injection in pre-filled syringe for dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose (1 ml) contains:

Active substance:

Bordetella bronchiseptica fimbriae¹: 88 - 399 U²

¹ Purified from strain Bb7 92932

² Antigenic mass ELISA units

Adjuvant:

dl- α -tocopheryl acetate: 74.7 mg

Excipients:

Qualitative composition of excipients and other constituents
Sodium chloride
Disodium hydrogen phosphate dihydrate
Sodium dihydrogen phosphate dihydrate
Polysorbate 80
Water for injections

Aqueous, white to nearly white suspension, mild creaming.

3. CLINICAL INFORMATION

3.1 Target species

Dogs.

3.2 Indications for use, for each target species

For active immunisation of dogs against *Bordetella bronchiseptica* to reduce clinical signs of upper respiratory tract disease and bacterial shedding post infection.

Onset of immunity: 2 weeks.

Duration of immunity: 7 months after primary vaccination.
1 year after revaccination.

3.3 Contraindications

None.

3.4 Special warnings

Vaccinate healthy animals only.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Not applicable.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Dogs:

Very common (> 1 animal / 10 animals treated):	Injection site swelling (\leq 2 cm, occasionally firm, may be present up to 25 days post-vaccination).
Common (1 to 10 animals / 100 animals treated):	Injection site swelling (\leq 3.5 cm, may be present up to 25 days post-vaccination ¹ and can be painful).
Very rare (< 1 animal / 10,000 animals treated, including isolated reports):	Hypersensitivity reaction. ²

¹ The swelling may uncommonly last for up to 35 days post-vaccination.

² If hypersensitivity reaction occurs, appropriate treatment should be administered without delay. Such reactions may evolve to a more severe condition which may be life-threatening.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the last section of the package leaflet for contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy

Can be used during pregnancy. The safety of this vaccine has not been investigated during the first 20 days of gestation.

3.8 Interaction with other medicinal products and other forms of interaction

Safety and efficacy data are available which demonstrate that this vaccine can be administered at the same time but not mixed with the live vaccines in the Nobivac range against canine distemper, canine contagious hepatitis caused by canine adenovirus type 1, canine parvovirus disease and respiratory disease caused by canine adenovirus type 2, where authorised.

Safety data are available which demonstrate that this vaccine can be administered at the same time but not mixed with the Nobivac range of vaccines mentioned above together with the live Nobivac parainfluenza vaccine and the inactivated vaccines in the Nobivac range against leptospirosis caused by *L. interrogans* serogroup Canicola serovar Canicola, *L. interrogans* serogroup Icterohaemorrhagiae serovar Copenhageni, *L. interrogans* serogroup Australis serovar Bratislava, and *L. kirschneri* serogroup Grippotyphosa serovar Bananal/Lianguang.

In addition, for the live canine parainfluenza vaccine there are antibody response data, and for the inactivated canine leptospirosis vaccines there are antibody response data and other immunity data which support the use of the vaccine at the same time but not mixed with the mentioned Nobivac range of vaccines.

When this vaccine is administered in association with the relevant Nobivac vaccines, the demonstrated safety and efficacy claims of the vaccine are the same as when this vaccine is administered alone.

The product information of the relevant Nobivac vaccines used in association with this vaccine should be consulted before administration.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

3.9 Administration routes and dosage

Subcutaneous use, 1 ml dose per vaccination.

Dogs can be vaccinated from the age of 6 weeks onwards.

Allow the vaccine to reach room temperature (15 °C – 25 °C) before use.

Primary vaccination:

Two vaccinations with an interval of 4 weeks.

Revaccination:

A single vaccination, administered 7 months after primary vaccination with this vaccine, is sufficient to maintain protection against *Bordetella bronchiseptica* for a further year. Thereafter, a single vaccination should be administered, annually. In case revaccination at 7 months is missed, a single vaccination within 12 months after primary vaccination is sufficient to extend protection against *Bordetella bronchiseptica* for a further year.

This vaccine can also be used for revaccination in a schedule where Nobivac KC has been used for primary vaccination. A single vaccination, administered one year after primary vaccination with Nobivac KC, is sufficient to prolong immunity against *Bordetella bronchiseptica* for another year.

Revaccination after primary vaccination with Nobivac KC:

One vaccination, annually.

For associated use:

When this vaccine is administered in associated use (i.e. not mixed) with another vaccine in the Nobivac range as indicated under section 3.8, the vaccines should be given subcutaneously, at the same time, at a different site. Dogs should not be younger than the minimum age recommended for the other Nobivac vaccine, as stated in the respective product information.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Not applicable.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal period(s)

Not applicable.

4. IMMUNOLOGICAL INFORMATION

4.1. ATCvet code: QI07AB03.

The subunit vaccine stimulates active immunity against *Bordetella bronchiseptica* infection in dogs.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Do not mix with any other veterinary medicinal product.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

5.3 Special precautions for storage

Store in a refrigerator (2 °C – 8 °C). Do not freeze.
Store in the original package in order to protect from light.

5.4 Nature and composition of immediate packaging

Type I glass pre-filled syringe, containing a plunger with a halogenobutyl end and closed with a halogenobutyl stopper.

Pack sizes:

Cardboard box with:

- 5 single dose pre-filled syringes (5 x 1 ml) and needles.
- 10 single dose pre-filled syringes (10 x 1 ml) and needles.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
Netherlands

7. MARKETING AUTHORISATION NUMBER

Vm 06376/3024

8. DATE OF FIRST AUTHORISATION

18 August 2020

9. DATE OF THE LAST REVISION OF THE SUMMARY OF PRODUCT CHARACTERISTICS

January 2025

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Gavin Hall
Approved: 10 January 2025